Résultats de recherche
Nombre de programmes trouvés : 21
Conférences
le
(1h16m11s)
EEHU 2014 Corps - Esprit session 4
... placebo contrevient-elle au contrat de confiance ? Martine TACHEAU, infirmière anesthésiste, C.H de Dreux. Edouard CREPIN, médecin rééducateur, C.H de Dreux. L'intrus qui venait de l'intérieur : le cancer, entre corps affecté et esprit divisé....
Voir la vidéo
Documentaires
le
(54m28s)
Aux frontières de la science - Les pouvoirs de l'esprit - Nimbus n°28
... avec le professeur Rhine. Il est apparu alors que certaines personnes semblent douées de perception extrasensorielle : clairvoyance, prémonition ou encore télépathie... De même, par simple effet de conviction, un placebo peut soigner de véritables...
Voir la vidéo
Label UNT Conférences
le
(57m35s)
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.
... blockade, who were randomized to add either placebo or ivabradine (pure HR slowing drug) during a median 22.9 months follow-up. The results of SHIFT unambiguously demonstrated the benefits of HR slowing (placebo-subtracted ivabradinemediated HR reduction...
Voir la vidéo
Label UNT Conférences
le
(26m40s)
Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)
... BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes.- More specifically in chronic hemodialysis...
Voir la vidéo
Label UNT Conférences
le
(20m6s)
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.
... that such agents may have therapeutic benefit in chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients...
Voir la vidéo
Label UNT Conférences
le
(10m18s)
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
... that such agents may have therapeutic benefit in chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients...
Voir la vidéo
Label UNT Conférences
le
(9m25s)
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).
... that such agents may have therapeutic benefit in chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients...
Voir la vidéo
Label UNT Conférences
le
(22m32s)
Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)
... chronic renal failure.- The ongoing BEACON trial assesses the efficacy of bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes.- More...
Voir la vidéo
Label UNT Conférences
le
(14m11s)
Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues.
... bardoxolone methyl relative to placebo in delaying progression to end-stage renal disease and cardiovascular deaths in patients with Stage 4 CKD and type 2 diabetes.- More specifically in chronic hemodialysis patients, results from the very few clinical trials...
Voir la vidéo
Conférences
le
(59m21s)
SIFUD-PP La Baule 2015 : Seven Up - Les 7 meilleures communications libres
... d'un essai contrôlé versus placebo en groupes parallèles. H. Colangeli Hagege, O. Cotelle, B. Savarieau, G. Cargill, L. Bueno, M. C. Cappelletti Photovaporisation prostatique par laser Greenlight chez les patients sondés : efficacité et facteurs...
Voir la vidéo